Equities research analysts expect Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) to report sales of $11.98 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Juniper Pharmaceuticals’ earnings. The highest sales estimate is $12.55 million and the lowest is $11.40 million. Juniper Pharmaceuticals posted sales of $11.56 million in the same quarter last year, which suggests a positive year over year growth rate of 3.6%. The firm is expected to issue its next earnings report on Tuesday, November 21st.

According to Zacks, analysts expect that Juniper Pharmaceuticals will report full-year sales of $11.98 million for the current year, with estimates ranging from $45.15 million to $48.44 million. For the next financial year, analysts expect that the business will report sales of $51.55 million per share, with estimates ranging from $48.07 million to $55.02 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that cover Juniper Pharmaceuticals.

Juniper Pharmaceuticals (NASDAQ:JNP) last posted its quarterly earnings data on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.13) by $0.10. Juniper Pharmaceuticals had a net margin of 13.94% and a return on equity of 21.49%. The company had revenue of $13.96 million for the quarter, compared to the consensus estimate of $11.84 million.

A number of brokerages have recently issued reports on JNP. BMO Capital Markets raised Juniper Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their price target for the company from $31.00 to $34.00 in a report on Friday, July 14th. HC Wainwright reaffirmed a “hold” rating on shares of Juniper Pharmaceuticals in a report on Monday, May 15th. Roth Capital set a $12.00 price target on Juniper Pharmaceuticals and gave the company a “buy” rating in a report on Saturday, May 6th. Finally, ValuEngine downgraded Juniper Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Two investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Juniper Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $23.00.

ILLEGAL ACTIVITY WARNING: “Juniper Pharmaceuticals, Inc. (JNP) Expected to Post Quarterly Sales of $11.98 Million” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another website, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/08/23/juniper-pharmaceuticals-inc-jnp-expected-to-post-quarterly-sales-of-11-98-million.html.

A number of hedge funds have recently bought and sold shares of the stock. Nationwide Fund Advisors boosted its stake in Juniper Pharmaceuticals by 5,500.0% in the second quarter. Nationwide Fund Advisors now owns 56,000 shares of the specialty pharmaceutical company’s stock worth $283,000 after buying an additional 55,000 shares during the period. JW Asset Management LLC boosted its stake in Juniper Pharmaceuticals by 10.0% in the second quarter. JW Asset Management LLC now owns 426,903 shares of the specialty pharmaceutical company’s stock worth $2,156,000 after buying an additional 38,771 shares during the period. Algert Global LLC boosted its stake in Juniper Pharmaceuticals by 10.8% in the second quarter. Algert Global LLC now owns 120,035 shares of the specialty pharmaceutical company’s stock worth $606,000 after buying an additional 11,720 shares during the period. Spark Investment Management LLC boosted its stake in Juniper Pharmaceuticals by 33.0% in the second quarter. Spark Investment Management LLC now owns 60,000 shares of the specialty pharmaceutical company’s stock worth $303,000 after buying an additional 14,900 shares during the period. Finally, Municipal Employees Retirement System of Michigan purchased a new stake in Juniper Pharmaceuticals during the second quarter worth approximately $1,192,000. Institutional investors own 36.61% of the company’s stock.

Shares of Juniper Pharmaceuticals (JNP) opened at 4.50 on Wednesday. The stock has a 50 day moving average of $4.87 and a 200-day moving average of $4.70. The firm has a market capitalization of $48.80 million, a P/E ratio of 5.81 and a beta of 0.28. Juniper Pharmaceuticals has a 12-month low of $3.65 and a 12-month high of $6.44.

Juniper Pharmaceuticals Company Profile

Juniper Pharmaceuticals, Inc is a women’s health therapeutics company. The Company is focused on developing therapeutics that address unmet medical needs in women’s health. It operates in two segments: product and service. The product segment is engaged in manufacturing and supplying CRINONE, the Company’s commercialized product.

Get a free copy of the Zacks research report on Juniper Pharmaceuticals (JNP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Juniper Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juniper Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.